Discovery Life Sciences

2024 has been a pivotal year for biopharma, marked by both challenges and remarkable progress. Milestones like CAR-T therapies gaining approvals for earlier-line cancer treatments and promising antibody-drug conjugate candidates poised for approval in the new year, set the stage for exciting developments in the coming year. As we gear up for 2025, let’s take a moment to reflect on some of Discovery’s highlights from this year. 

Join us at #USCAP in Boston from March 22-27 and discover how Discovery's Biomarker Academy and Peri-and Post-Approval Services boost lab competency and pathologist proficiency to accelerate the adoption of clinical diagnostic biomarkers through training development, peer-to-peer pathologist training, concordance studies, and more.     Reach out to our expert Biomarker Academy team members below to schedule a meeting! - Dr. Gudrun Bänfer, Client Relations and Business Expansion Manager  - Riem Adjam, Senior Director Global Peri & Post-Approval Services #USCAP2025 

Are you attending Precision Med Tri-Con? Stop by Booth 9 to grab a beverage at our hydration station and meet the team. Let’s connect!  Shawn Fahl, Meredith Osborn MS, Dan Searson, T. Scott Reid, Andy L. Chiang, Nadia DeStefano #TRICON #TRICON2025 

Colorectal cancer is one of the most common cancers in the US—but it’s also one of the most preventable. When detected early, the five-year relative survival rate is 91.1%.However, this drops significantly as the cancer advances:   https://lnkd.in/gEvaJJ8h Early detection saves lives. Routine screening can catch colorectal cancer before it spreads, dramatically improving outcomes.  Let’s raise awareness and make regular screening a priority. #ColorectalCancer #Prevention #DressInBlueDay 

Tri-Con 2025 update! Don’t miss Dr. Shawn Fahl at the panel discussions over Tech Trends in Precision Medicine on Wednesday March 12, at 4:05 PM. In this plenary discussion session, Dr. Fahl will join a distinguished panel to share insights on emerging innovations in precision medicine.  Attend the poster presentation titled Cell-Free DNA and Beyond: A Comprehensive Evaluation of Liquid Biopsy Workflows Across in a Global Clinical Biorepository    See you there!  #TRICON #TRICON2025 

It’s difficult to evaluate the metabolism of large and poorly permeabilized drug compounds in the conventional in vitro liver models due to their size, structure, and limited membrane permeability. Our new blog post explores how these factors impact drug development and how permeabilized hepatocytes offer a novel solution to overcome these challenges. Read the new blog post: https://lnkd.in/edK3NpXP #hepatocytes #ADMET 

In honor of Women’s History Month, Discovery is spotlighting five extraordinary women scientists who have shattered gender barriers and reshaped the course of science. Their groundbreaking work has deepened our understanding of disease, fueled medical breakthroughs, and transformed lives—driving real change and inspiring future generations: Jane Cooke Wright (1919 – 2013)   Renowned cancer researcher best known for her pioneering work in chemotherapy. Dr. Wright and her team were the first to identify methotrexate, one of the foundational chemotherapy drugs, to treat solid tumors, including leukemia, Hodgkin’s disease, lymphosarcoma, melanoma, breast cancer, and prostate cancer.   Irene Uchida  A Canadian cytogeneticist whose research helped establish the link between prenatal X-ray exposure and an increased risk of having babies with Down syndrome. Dr. Uchida’s work led to the creation of Canada’s first cytogenetics program and the development of a diagnostic blood test to detect chromosomal abnormalities like trisomy 18 in infants. Katalin Karikó  Dr. Karikó’s research in mRNA technology laid the foundation for the COVID-19 vaccine, which turned the tide in the battle against the SARS-CoV-2 virus. Her work has opened new possibilities for developing mRNA-based therapies for other diseases. Jennifer Doudna & Emmanuelle Charpentier  Awarded the 2020 Nobel Prize in Chemistry for their discovery of the CRISPR/Cas9 gene editing technology, this scientific duo has revolutionized genetic research, enabling precise DNA modifications that are leading to advancements in gene therapy, agriculture, and disease prevention.  #WomensHistoryMonth #WomenInSTEM 

We are excited to showcase our recent scientific works at Precision Med Tri-Con 2025. Look out for our luncheon presentation led by Dr. Shawn Fahl:    Title: Biorepository to Breakthroughs: Accelerating Development with Spatial and Transcriptomic Analyses on March 11, 2025, 12:25 PM – 12:55 PM (Spatial Biology and Single-Cell Multiomics Program).     Attend the poster presentation titled Cell-Free DNA and Beyond: A Comprehensive Evaluation of Liquid Biopsy Workflows Across in a Global Clinical Biorepository. Schedule a meeting with our team today: https://lnkd.in/gV7rKQEs  #TRICON #TRICON2025 

Cell therapy’s focus is expanding beyond cancer in 2025 with increasing interest in applying CAR-T and T cell engagers (TCEs) to autoimmune diseases like lupus and multiple sclerosis. Read more about how this shift is changing the biopharma landscape:  https://lnkd.in/ee9qpHKG  At Discovery, we support the evolving CGT industry with high-quality starting cellular materials that help drive innovation from research to commercialization.

We are excited to announce the official launch of our tumoroid cell lines at the upcoming Precision Med Tri-Con 2025, from March 11-13 in San Diego.  Read full press release: https://lnkd.in/eyNBd3V2 “Our tumoroid cell lines are a transformative tool that will eliminate major barriers to oncology research, giving scientists a powerful, predictive tool to identify life-changing therapies faster,” said McLean Collins, Discovery’s president of Biospecimens Products & Services.“This product also represents Discovery’s continued commitment to driving innovation in cancer research and complements our cell biology offerings in CFC and ADC assays along with our 10X single cell portfolio." Our strategic investments in advanced technologies, such as tumoroids and AI-powered pathology workflow, empower our customers with actionable, quantitative insights. #tumoroids #cancerorganoids #tricon2025